Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.30B | 52.94B | 46.58B | 44.25B | 37.11B | 29.27B |
| Gross Profit | 41.60B | 39.70B | 34.45B | 28.04B | 22.60B | 21.66B |
| EBITDA | 18.84B | 14.86B | 13.20B | 8.63B | 4.59B | 8.04B |
| Net Income | 8.45B | 6.89B | 6.06B | 3.28B | 109.85M | 3.39B |
Balance Sheet | ||||||
| Total Assets | 112.42B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B |
| Cash, Cash Equivalents and Short-Term Investments | 7.11B | 5.65B | 5.91B | 6.24B | 6.37B | 7.95B |
| Total Debt | 32.84B | 30.11B | 28.41B | 29.14B | 30.69B | 20.38B |
| Total Liabilities | 67.61B | 63.16B | 61.95B | 59.42B | 66.08B | 51.09B |
| Stockholders Equity | 44.72B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
Cash Flow | ||||||
| Free Cash Flow | 8.72B | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B |
| Operating Cash Flow | 13.39B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B |
| Investing Cash Flow | -6.06B | -7.98B | -4.06B | -2.96B | -11.06B | -285.00M |
| Financing Cash Flow | -6.99B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Risk Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £71.92B | 13.23 | 36.44% | 3.34% | 2.73% | 119.38% | |
76 Outperform | £194.22B | 30.25 | 22.34% | 1.55% | 10.20% | 40.57% | |
71 Outperform | £31.87B | 21.29 | 9.35% | 1.52% | -2.12% | 42.10% | |
70 Outperform | £12.02B | 32.64 | 9.30% | 2.30% | 2.51% | 56.56% | |
67 Neutral | £3.89B | 13.61 | 15.66% | 4.03% | 3.73% | 27.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
AstraZeneca Corporate Events
AstraZeneca reported strong financial performance for the first nine months of 2025, with total revenue increasing by 11% to $43.2 billion, driven by growth in all therapy areas, especially oncology. The company achieved 16 positive Phase III trial readouts and 31 major approvals, reinforcing its pipeline strength. AstraZeneca is also expanding its operations in the US, including a $4.5 billion manufacturing facility in Virginia, and has reached a historic agreement with the US government to lower drug costs, which is expected to enhance its market positioning and stakeholder relations.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £142.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced that its shareholders have approved a resolution to adopt new articles of association, facilitating the harmonization of its equity listing structure across London, Stockholm, and New York. This move is expected to provide AstraZeneca with greater flexibility to access a broader pool of capital, particularly in the US, and reflects strong shareholder support. The new structure is anticipated to enhance AstraZeneca’s market presence and investment opportunities as it continues to expand in its growing markets.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £142.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced that as of 31 October 2025, its issued share capital with voting rights consists of 1,550,712,906 ordinary shares, with none held in Treasury. This figure is crucial for shareholders to determine their notification obligations under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, potentially impacting shareholder engagement and regulatory compliance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £142.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Koselugo (selumetinib) has been approved in the EU for treating symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1), based on the KOMET Phase III trial results. This approval marks a significant advancement in the treatment landscape for NF1, extending the benefits of Koselugo from pediatric to adult patients, and highlights AstraZeneca’s commitment to addressing unmet needs in the rare disease community.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £15000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca, in collaboration with Amgen, announced the European Union approval of Tezspire (tezepelumab) for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults who have not responded to standard therapies. This approval, based on the successful results of the WAYPOINT Phase III trial, marks a significant advancement in treatment options for CRSwNP, potentially reducing the need for surgery and systemic corticosteroids, and reinforcing AstraZeneca’s position in addressing epithelial-driven inflammation.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £145.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Amgen’s Tezspire has been approved by the US FDA for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), expanding its indications beyond severe asthma. This approval, based on the successful results of the WAYPOINT Phase III trial, positions Tezspire as a novel treatment option that significantly reduces the need for surgeries and systemic corticosteroid use, offering relief to millions affected by this condition. The approval is expected to enhance AstraZeneca’s market position in respiratory and immunology, reflecting its commitment to transforming patient care in chronic respiratory and immune-mediated diseases.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £137.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Saphnelo (anifrolumab) has been recommended for approval in the EU for self-administration via a pre-filled pen for adult patients with systemic lupus erythematosus (SLE). This recommendation by the CHMP is based on the TULIP-SC Phase III trial results, which demonstrated a significant reduction in disease activity. The approval could enhance patient access to Saphnelo, offering a convenient once-weekly option that aligns with updated treatment guidelines emphasizing reduced steroid use. This development positions AstraZeneca to further expand its presence in the autoimmune disease treatment market, potentially benefiting stakeholders by addressing unmet needs in SLE management.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £137.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced a historic agreement with the US Government to lower prescription medicine costs for American patients, aligning prices with those in wealthy countries. This agreement includes a $50 billion investment in US manufacturing and R&D, supporting domestic sourcing and innovation, and aims to generate $80 billion in revenue by 2030. The initiative also involves AstraZeneca’s participation in the TrumpRx.gov platform for discounted direct-to-consumer sales and a delay in Section 232 tariffs, enhancing the company’s US operations and economic contributions.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced that its drug, baxdrostat, met the primary endpoint in the Bax24 Phase III trial, showing a significant reduction in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension. This breakthrough suggests a potential shift in treatment approaches for patients with uncontrolled hypertension, as baxdrostat offers a durable, once-daily regimen that could improve blood pressure management and reduce cardiovascular risks. The company plans to advance regulatory filings and expand baxdrostat’s use across other conditions where aldosterone plays a critical role, such as primary aldosteronism and chronic kidney disease.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £126.50 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Daiichi Sankyo announced significant results from the TROPION-Breast02 Phase III trial, where their drug Datroway showed a statistically significant improvement in overall and progression-free survival for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy. This breakthrough positions Datroway as a potential new standard of care, offering hope for patients with limited treatment options and potentially impacting AstraZeneca’s market position in oncology.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £13991.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced that as of September 30, 2025, its issued share capital with voting rights consists of 1,550,701,945 ordinary shares, with no shares held in Treasury. This information is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca, in collaboration with Daiichi Sankyo, announced positive results from the DESTINY-Breast05 Phase III trial, showcasing Enhertu’s significant improvement in invasive disease-free survival for patients with high-risk HER2-positive early breast cancer compared to T-DM1. These findings, along with previous results from the DESTINY-Breast11 trial, reinforce Enhertu’s potential as a foundational treatment option in curative-intent settings, potentially altering the treatment landscape for HER2-positive early breast cancer and offering new hope for patients at high risk of disease recurrence.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £12052.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced plans to harmonize its share listing structure across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange. This move involves a direct listing of AstraZeneca shares on the NYSE, replacing the existing US ADRs on Nasdaq, to create a global listing for global investors. The company aims to broaden its investor base and enhance its access to capital markets, particularly in the US, which hosts the largest and most liquid public markets. Despite these changes, AstraZeneca will remain headquartered and tax resident in the UK, continuing its inclusion in the FTSE 100 and OMX Stockholm 30 indices, and adhering to UK governance standards. This strategic move is expected to support AstraZeneca’s long-term growth by reaching a broader mix of global investors.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £12052.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced that Karen Knudsen, a Non-Executive Director, acquired 9 American Depositary Shares in the company through the reinvestment of the first interim dividend for the year ending December 2025. This transaction highlights the ongoing engagement of AstraZeneca’s leadership in the company’s financial activities, potentially reinforcing investor confidence and reflecting a positive outlook on the company’s future performance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Koselugo (selumetinib), an oral MEK inhibitor, has been recommended for approval by the CHMP in the European Union for treating symptomatic, inoperable plexiform neurofibromas in adults with neurofibromatosis type 1. This recommendation is based on the KOMET Phase III trial, which demonstrated a 20% objective response rate in tumor size reduction, highlighting the urgent need for targeted treatments in this patient population. The approval would extend Koselugo’s reach, building on its established use in pediatric patients and its recent approval in Japan and other countries, potentially offering a new treatment option for adults and enhancing AstraZeneca’s position in the rare disease market.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval by the European Medicines Agency’s CHMP for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. This recommendation is based on the successful results of the WAYPOINT Phase III trial, which demonstrated significant reductions in nasal polyp severity and nasal congestion, along with a near-complete elimination of the need for surgery and reduced corticosteroid use. If approved, Tezspire will offer a new treatment option for CRSwNP, addressing the unmet needs of patients who do not find relief with current therapies. This development strengthens AstraZeneca’s position in respiratory care and highlights its commitment to transforming treatments for chronic and challenging conditions.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced positive interim results from the Phase III TULIP-SC trial, demonstrating that subcutaneous administration of Saphnelo significantly reduces disease activity in patients with systemic lupus erythematosus (SLE). The trial’s success supports the efficacy and safety of Saphnelo, potentially expanding its accessibility to more patients and aligning with updated clinical guidelines that emphasize remission and reduced corticosteroid use. The results are under regulatory review and will be presented at the upcoming American College of Rheumatology meeting.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £150.13 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced that its RESOLUTE Phase III trial for Fasenra (benralizumab) in treating chronic obstructive pulmonary disease (COPD) did not meet the primary endpoint of statistical significance, despite showing numerical improvement. The trial’s safety and tolerability profile were consistent with known data, and the company plans to analyze the full data set for further insights. Fasenra is already approved for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis in multiple countries, and the results of this trial may impact its future applications and regulatory reviews.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £150.13 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca PLC announced that as of August 31, 2025, its issued share capital with voting rights consists of 1,550,692,963 ordinary shares, with no shares held in Treasury. This figure is relevant for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced that a TR-1 notification submitted by The Capital Group Companies, Inc. was provided in error and advised shareholders to disregard it. Instead, they should refer to the TR-1 notification announced on 21 August 2025. This clarification helps maintain accurate shareholder information and ensures transparency in AstraZeneca’s communications.
The most recent analyst rating on (GB:AZN) stock is a Hold with a £110.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
In a recent clinical study update, AstraZeneca is evaluating the pharmacokinetics, safety, tolerability, and immunogenicity of a single inhaled dose of AZD8630 in adolescents with asthma. Officially titled ‘A Phase I, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Inhaled AZD8630 in Adolescents With Asthma,’ the study aims to assess the performance of the dry powder inhaler used for administration.
The DESTINY-Endometrial01 study, officially titled ‘An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer,’ aims to evaluate the efficacy of T-DXd combined with either rilvegostomig or pembrolizumab compared to standard chemotherapy with pembrolizumab. This study is significant as it targets a specific subset of endometrial cancer patients, potentially offering new first-line treatment options.
Study Overview: The Acalabrutinib Real World Italian obSErvational Study (ARISE) aims to evaluate the time to treatment discontinuation and reasons for discontinuation of acalabrutinib in patients with chronic lymphocytic leukemia (CLL) in Italy. This study is significant as it provides the first real-world data on acalabrutinib’s use in Italy, following its EMA approval and AIFA reimbursement.
AstraZeneca has launched a pioneering observational study titled ‘Implementation of a Lung Cancer Screening Program in a Public Service, Using Low-dose Tomography and Metabolomics Evaluation.’ The study aims to assess the effectiveness of a lung cancer screening program among smokers within a public health service setting, focusing on early detection and intervention.
AstraZeneca has initiated a significant clinical study titled ‘A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies.’ The study aims to evaluate the safety and effectiveness of AZD9829, a promising drug for treating CD123-positive hematological cancers.
AstraZeneca has launched a new clinical study titled ‘A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE).’ The study aims to evaluate the effectiveness of tezepelumab in treating chronic rhinosinusitis with nasal polyposis (CRSwNP), particularly for patients eligible for surgery, with or without asthma. This research is significant as it could provide a non-surgical treatment alternative for CRSwNP patients.
Amgen Inc. and AstraZeneca have initiated a Phase 3 clinical study titled ‘A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)’. The study aims to evaluate the efficacy of adding tarlatamab to the existing treatment regimen of durvalumab, carboplatin, and etoposide, with a focus on improving overall survival rates in patients with untreated extensive stage small-cell lung cancer.
Study Overview: AstraZeneca is conducting a study titled Chronicling the COPD Patient Journey and Change in Impact of a Single Inhaler Combination Therapy on COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF] (CHRONICLES COPD). The study aims to evaluate changes in clinical and patient-reported outcomes over six months following the initiation of BGF treatment in COPD patients, highlighting its significance in improving patient quality of life.
AstraZeneca is currently recruiting participants for a Phase 1 study titled ‘A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma.’ This study aims to assess the safety, tolerability, and efficacy of the dual CAR T-cell therapy in treating Multiple Myeloma, a significant step in advancing early-line treatment options for this condition.
AstraZeneca is conducting a Phase Ib clinical study titled A Phase Ib Open Label Positron Emission Tomography Study to Assess Changes in Intestinal [11C]AZ14132516 Uptake Following Administration of Multiple Doses of AZD7798 to Patients With Crohn’s Disease. The study aims to evaluate changes in intestinal uptake of the radioligand [11C]AZ14132516 after administering multiple doses of AZD7798 to patients with Crohn’s disease, which could provide insights into the drug’s effectiveness and safety.
Study Overview: AstraZeneca is conducting a Phase III study titled ‘A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)’. The study aims to evaluate the efficacy of a triple therapy inhaler on cardiopulmonary outcomes in patients with COPD at elevated risk, highlighting its potential significance in improving treatment options for this population.
The GEMINI-PeriOp GC study, officially titled ‘A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma,’ aims to assess the safety and effectiveness of new drug combinations in treating locally advanced resectable gastroesophageal adenocarcinoma. This study is significant as it explores innovative treatment options for a challenging cancer type.
The Capital Group Companies, Inc. has adjusted its holdings in AstraZeneca PLC, crossing a threshold of 4.997854% in voting rights as of August 19, 2025. This change in holdings may impact AstraZeneca’s shareholder dynamics and influence its strategic decisions, reflecting ongoing shifts in investor confidence and market positioning.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has completed a Phase 3 clinical study titled ‘RESOLUTE,’ aimed at evaluating the efficacy and safety of Benralizumab in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) who have a history of frequent exacerbations and elevated peripheral blood eosinophils. The study’s primary objective was to assess the treatment’s impact on reducing COPD exacerbations, a significant concern for patients with this condition.
AstraZeneca is currently conducting a Phase 2a clinical study titled ‘A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma.’ The study aims to evaluate the efficacy and safety of Atuliflapon, a new oral drug, in treating adults with moderate to severe uncontrolled asthma, highlighting its potential significance in addressing unmet medical needs in this patient population.
AstraZeneca is currently conducting a Phase 3 clinical study titled ‘DESTINY-Biliary Tract Cancer-01’ to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig compared to the standard-of-care treatments in patients with advanced HER2-expressing biliary tract cancer. The study aims to assess whether these experimental therapies can offer better outcomes than the existing standard treatments of gemcitabine, cisplatin, and durvalumab.
AstraZeneca’s latest clinical study, titled A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies, aims to evaluate the bioavailability and pharmacokinetics of Saruparib in patients with advanced solid tumors. This study is significant as it explores the drug’s potential effectiveness and safety, contributing to the development of new cancer therapies.
AstraZeneca has initiated a Phase I clinical study titled ‘A Phase I, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Inhaled AZD8630 in Adolescents With Asthma.’ The study aims to assess the pharmacokinetic profile, safety, tolerability, and immunogenicity of a single inhaled dose of AZD8630 in adolescent asthma patients, as well as the performance of the dry powder inhaler used for administration.
AstraZeneca, in collaboration with Daiichi Sankyo and other partners, is conducting a Phase III clinical study titled ‘DESTINY-Endometrial01.’ The study aims to evaluate the efficacy of Trastuzumab Deruxtecan (T-DXd) combined with Rilvegostomig or Pembrolizumab as a first-line treatment for HER2-expressing, mismatch repair proficient endometrial cancer. This research is significant as it explores alternative therapies to standard chemotherapy, potentially improving patient outcomes.
AstraZeneca is conducting a Phase 2a clinical study titled ‘A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma.’ The study aims to evaluate the efficacy and safety of Atuliflapon, a potential new treatment for adults with moderate to severe uncontrolled asthma, over a 12-week period.
AstraZeneca recently completed a Phase 3 study titled A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE). The study aimed to assess the efficacy and safety of Benralizumab in patients with moderate to very severe COPD who have a history of frequent exacerbations and elevated blood eosinophils.
AstraZeneca is currently recruiting for a Phase I clinical study titled ‘A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies.’ This study aims to evaluate the bioavailability and pharmacokinetics of Saruparib, a PARP inhibitor, in patients with advanced solid tumors, offering potential insights into its therapeutic efficacy and safety.
AstraZeneca has launched a Phase 3 clinical study titled ‘DESTINY-Biliary Tract Cancer-01’ to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig against the standard-of-care (SoC) treatment in patients with advanced HER2-expressing biliary tract cancer (BTC). The study aims to determine whether the experimental drugs can provide a better treatment alternative to the current SoC, which includes Gemcitabine, Cisplatin, and Durvalumab.
AstraZeneca announced that Aradhana Sarin, the Executive Director and Chief Financial Officer, sold 9,563 of the company’s ordinary shares on August 14, 2025, at a price of £115.117 per share. This transaction is part of the company’s regulatory compliance with the EU Market Abuse Regulation, reflecting internal managerial decisions that might influence stakeholder perceptions and market dynamics.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca is conducting a study titled ‘Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania.’ The study aims to evaluate the real-world outcomes of acalabrutinib in patients with chronic lymphocytic leukemia (CLL) in Romania, focusing on the time to treatment discontinuation and other clinical characteristics.
AstraZeneca’s recent clinical study, titled ‘A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours,’ aims to evaluate the safety, tolerability, and pharmacokinetics of the drug combination in patients with advanced solid tumors. This study is significant as it explores a novel therapeutic approach for treating refractory solid tumors.
AstraZeneca is currently conducting a Phase 2b study titled ‘APPRECIATE’ to evaluate the efficacy, safety, and tolerability of AZD2373 in individuals with APOL1-Mediated Kidney Disease (AMKD). The study aims to determine if AZD2373 can significantly reduce the urine albumin-to-creatinine ratio (UACR) compared to a placebo over a 30-week period. This research is crucial for developing targeted treatments for patients with high-risk APOL1 genotypes.
Study Overview: AstraZeneca is conducting a Phase I/II study titled ‘ATHENA’ to evaluate the safety, cellular kinetics, and efficacy of AZD5851, a CAR-T therapy targeting GPC3 in adults with advanced/recurrent hepatocellular carcinoma (HCC). This study is significant as it explores a novel treatment for patients who have not responded to or cannot tolerate existing therapies.
AstraZeneca’s latest clinical study, titled ‘Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),’ aims to evaluate the efficacy and safety of combining capivasertib with CDK4/6 inhibitors and fulvestrant. This study targets hormone receptor-positive and HER2-negative breast cancer that is locally advanced or metastatic, focusing on patients who have not received prior endocrine therapy in the advanced setting.
AstraZeneca is conducting a Phase III study titled A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2. The study aims to evaluate the efficacy and safety of AZD0901 as a treatment for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin18.2, compared to standard therapies chosen by investigators.
AstraZeneca has announced a new clinical study titled ‘Anifrolumab Pregnancy Study,’ aimed at assessing the pregnancy-related safety of Anifrolumab in women with Systemic Lupus Erythematosus (SLE). This non-interventional study seeks to evaluate congenital malformations and adverse pregnancy outcomes in women exposed to Anifrolumab compared to those receiving other standard treatments.
Study Overview: AstraZeneca, in collaboration with Parexel, is conducting a Phase III study titled ‘LATIFY’ to evaluate the efficacy and safety of ceralasertib plus durvalumab compared to docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after prior anti-PD-(L)1 therapy and platinum-based chemotherapy. This study aims to provide an alternative treatment for patients without actionable genomic alterations, potentially improving outcomes in this challenging patient population.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIIb clinical study titled ‘Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA).' The study aims to compare the effect of a budesonide/albuterol metered-dose inhaler (BDA MDI) with an albuterol sulfate metered-dose inhaler (AS MDI) on the rate of severe asthma exacerbations in adolescents with a history of asthma exacerbations.
The ZEAL Study, officially titled ‘A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension,’ aimed to evaluate the effectiveness and safety of combining zibotentan and dapagliflozin in treating liver cirrhosis with portal hypertension.
Study Overview: AstraZeneca is conducting a Phase IIIb clinical study titled TRITON to evaluate the efficacy of durvalumab plus tremelimumab combined with chemotherapy versus pembrolizumab with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with specific genetic mutations. This study aims to improve treatment outcomes for patients with challenging genetic profiles.
AstraZeneca, in collaboration with Daiichi Sankyo and Iqvia Pty Ltd, is conducting a clinical study titled ‘ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors.’ The study aims to evaluate the comparative effectiveness of Trastuzumab Deruxtecan (T-DXd) versus standard of care (SoC) in patients with HER2 IHC3+ expressing solid tumors, focusing on overall survival. This research is significant as it uses real-world data to provide insights into the treatment’s effectiveness across various cancers, including non-small cell lung cancer, colorectal cancer, and others.
AstraZeneca has announced a new clinical study titled ‘DESTINY-PANTUMOUR04’ aimed at evaluating the effectiveness of Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive solid tumors. The study targets individuals who have previously undergone systemic treatment and have no satisfactory alternative options, highlighting its significance in offering potential new hope for these patients.
AstraZeneca’s recent clinical study update focuses on evaluating the efficacy and safety of Selumetinib in combination with Docetaxel for patients with KRAS mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Officially titled ‘SELECT 1,’ the study aims to provide a second-line treatment option for this specific patient group, assessing progression-free survival, overall survival, and other key outcomes.
AstraZeneca is conducting a Phase 1 clinical study titled ‘A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma (B-NHL), a significant step in addressing this challenging cancer type.
AstraZeneca recently completed the EROS+CP Japan Study, officially titled ‘Exacerbations and Real-World Outcomes Including Cardiopulmonary Events Among Patients with Chronic Obstructive Pulmonary Disease Initiating Budesonide/Glycopyrronium/Formoterol.’ This study aimed to assess the timing of initiating the BGF treatment following a COPD exacerbation and its impact on subsequent exacerbations and cardiopulmonary events in Japan, highlighting its significance in managing COPD effectively.
AstraZeneca has announced an update on its ongoing clinical study titled ‘Pooled Analysis of Multi-country, Open-label Single-arm, Non-interventional, Multi-center, Cohort Studies of Real-world Outcomes in New Users of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting.’ The study aims to analyze real-world outcomes in patients initiating BGF therapy, a combination treatment for moderate to severe COPD, across multiple countries.
AstraZeneca is conducting a Phase II clinical study titled ‘A Participant- and Investigator-blind, Randomized, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair With AZD7798 in Patients With Active Ileal Crohn’s Disease and an Ileostomy (CALLISTO)’. The study aims to assess the safety, tolerability, and mucosal repair effects of AZD7798 compared to a placebo in patients with active ileal Crohn’s disease who have an ileostomy.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study titled A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of AZD1613 Following Single and Multiple Dose Administration in Healthy Participants. The study aims to evaluate the safety and tolerability of AZD1613 in healthy individuals, including those of Japanese and Chinese descent, marking a significant step in the drug’s development.
AstraZeneca has announced a new observational study titled ‘Anifrolumab Malignancy and Serious Infections Study.’ The study aims to assess the incidence of serious infections and malignancies in systemic lupus erythematosus (SLE) patients exposed to Anifrolumab compared to those receiving standard care. This research is significant as it seeks to understand the safety profile of Anifrolumab, a drug used to treat moderate to severe SLE.
AstraZeneca, in collaboration with Parexel International, initiated a clinical study titled A Phase I, Randomized, Partial Double-blind, Single Dose, 3 Way Cross Over Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol for BGF MDI HFO Compared With BGF MDI HFA Using an AeroChamber Plus Flow Vu Spacer and to Compare the Lung Exposure of BGF MDI HFO With a Spacer to BGF MDI HFO Without a Spacer. The study aims to evaluate the bioequivalence of a new formulation of a metered dose inhaler (MDI) using a next-generation propellant compared to the existing formulation, focusing on lung exposure.
AstraZeneca has launched a Phase II clinical study titled ‘A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria.’ The study aims to evaluate the efficacy, safety, and tolerability of a combination of zibotentan and dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease (CKD) and high proteinuria. This research is significant as it could provide crucial data for the approval process of this innovative treatment in the Eurasian Economic Union.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD4248. This study targets healthy participants and those with chronic kidney disease and type 2 diabetes, aiming to assess the feasibility of home-based creatinine measurement.
AstraZeneca has initiated a Phase III clinical study titled ‘Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)’ to assess the safety and efficacy of anifrolumab in treating systemic sclerosis. This study aims to provide a new therapeutic option for patients with this rare autoimmune disease, which currently has limited treatment options.
Study Overview: AstraZeneca recently completed a Phase II study titled ‘A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)’. The study aimed to assess the safety and efficacy of AZD3152 in adults at high risk of severe COVID-19 due to compromised immune responses post-vaccination.
AstraZeneca’s latest study, titled ‘AQUALIS: Quality of Life of Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France,’ aims to evaluate the real-world quality of life (QoL) of patients with Chronic Lymphocytic Leukemia (CLL) treated with acalabrutinib. This retrospective observational study leverages data from the PLATON database to assess QoL from treatment initiation up to 12 months, providing insights into patient experiences outside of clinical trials.
AstraZeneca is currently conducting a Phase Ib clinical study titled A Phase Ib, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET). The study aims to evaluate the effects of AZD3427 on renal perfusion in patients with heart failure and reduced renal function, which could have significant implications for treating these conditions.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I study titled A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours. The study aims to assess how ceralasertib affects the pharmacokinetics of three other drugs in patients with advanced solid tumors, providing insights into potential treatment combinations.
AstraZeneca, in collaboration with ModernaTX, Inc., has completed a Phase 1 clinical study titled A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade. The study aimed to evaluate the safety and tolerability of mRNA-2752, a novel therapeutic designed for patients with advanced malignancies, including solid tumors and lymphoma.
AstraZeneca has launched the EPIC-ATTR study, a Phase 3 clinical trial aimed at evaluating the efficacy of eplontersen in reducing transthyretin levels and assessing its long-term safety in Chinese patients with transthyretin amyloid cardiomyopathy. This study is significant as it targets a specific heart condition that can lead to severe cardiac issues, focusing on both hereditary and wild-type forms of the disease.
AstraZeneca’s iCaReMe Global Registry is a real-world multinational study designed to assess the management and quality of care for patients with type 2 diabetes, hypertension, heart failure, and chronic kidney diseases. The study aims to gather comprehensive data on patient characteristics, disease management, healthcare utilization, and outcomes across various countries, providing valuable insights into current clinical practices.
AstraZeneca is currently conducting a national multicenter non-interventional study titled ‘CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia.’ The study aims to assess diagnostic and treatment approaches for patients with unresectable locally advanced non-small cell lung cancer (LA NSCLC) and limited-stage small cell lung carcinoma (LS-SCLC) across 50 major oncology centers in Russia. This research is significant as it seeks to understand real-world practices and outcomes in treating these conditions.
The Chronic Kidney Disease Registry Platform Study, officially titled as such, is a multicenter, prospective, observational study led by AstraZeneca. Its primary aim is to establish a registry platform by collecting comprehensive data on chronic kidney disease (CKD) patients in China. This includes demographics, clinical characteristics, and treatment patterns to identify gaps in current practices and develop risk prediction models for CKD progression.
AstraZeneca is conducting a real-world study titled ‘Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia.’ The study aims to evaluate the efficacy of Tezepelumab in patients with severe asthma, focusing on patient-reported outcomes and demographic characteristics.
AstraZeneca, in collaboration with Parexel International, has completed a Phase I clinical study titled A Phase I, Randomised, Single-dose, Open-label, 3-period, 3-treatment, 3-way Crossover Study to Assess the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants. The study aimed to evaluate how food intake affects the pharmacokinetics of the drug combination balcinrenone/dapagliflozin, as well as the pharmacokinetics of balcinrenone when administered with a P-gp inhibitor in healthy individuals.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05). The study aims to evaluate the efficacy and safety of Dato-DXd, with or without durvalumab, against standard chemotherapy options combined with pembrolizumab in patients with advanced triple-negative breast cancer.
AstraZeneca is conducting a Phase 3 study titled ‘A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus.’ The study aims to assess the efficacy and safety of subcutaneous anifrolumab in adults with moderate-to-severe systemic lupus erythematosus (SLE) who are already on standard therapy. This research is significant as it could offer a new treatment option for SLE patients.
AstraZeneca is currently conducting a Phase III clinical study titled A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death. The study aims to assess the efficacy of combining Baxdrostat with Dapagliflozin in reducing the risk of heart failure and cardiovascular death among patients with type 2 diabetes and established cardiovascular disease.
AstraZeneca is currently recruiting for a clinical study titled ‘A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma’. The study aims to assess the safety and efficacy of AZD0305, a new drug for patients with relapsed or refractory multiple myeloma, who have undergone at least three prior treatments.
AstraZeneca’s ROSY-D study, officially titled ‘Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab,’ aims to provide continued treatment for patients who have benefited from previous oncology studies involving Durvalumab. This study is significant as it seeks to extend the clinical benefits for patients who have shown positive outcomes in earlier trials.
Amgen Inc. and AstraZeneca have initiated a Phase 3 clinical study titled ‘A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312).’ This study aims to evaluate the efficacy of adding tarlatamab to the existing treatment regimen of durvalumab, carboplatin, and etoposide in improving overall survival for patients with extensive stage small-cell lung cancer (ES-SCLC).
AstraZeneca is currently recruiting for a multicentre observational study titled A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation. The study aims to evaluate treatment approaches and the prevalence of HER2 and PD-L1 positive statuses in bladder cancer patients across various stages, providing valuable insights into the disease’s progression and treatment efficacy in the Russian Federation.
AstraZeneca is conducting an open-label Phase 3 study to evaluate the safety and efficacy of Sodium Zirconium Cyclosilicate (SZC) in pediatric patients with hyperkalaemia. The study aims to assess the ability of SZC to achieve and maintain normal potassium levels in children under 18 years of age. Approximately 140 participants will be enrolled across 46 sites in Europe and North America, with the study divided into three phases: Correction Phase (CP), Maintenance Phase (MP), and Long-term Maintenance Phase (LTMP).
In a recent update, AstraZeneca has completed its observational study titled ‘OLAP’ (OLAparib Regulatory Post-marketing Surveillance), officially known as Lynparza Tablet (Olaparib) Regulatory Post-Marketing Surveillance. The study aimed to assess the safety and effectiveness of the Lynparza tablet in a real-world setting for patients in South Korea, particularly focusing on those with ovarian cancer who are Homologous Recombination Deficiency (HRD) positive.
Study Overview: AstraZeneca is conducting a clinical study titled ‘A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)’. The study aims to evaluate the safety, tolerability, and efficacy of AZD0120 in adults with refractory SLE, a challenging autoimmune condition.
AstraZeneca has launched a multicenter, observational study titled ‘Multicenter, Observational, Prospective Study of Molecular Profiling in Advanced and Aggressive Endometrial Cancer Patients and 1-st Line Treatment Approaches in Russian Federation.’ The study aims to gather real-world data on advanced endometrial cancer, focusing on molecular profiling and first-line treatment strategies in Russia. This research is significant as it seeks to enhance understanding and treatment of aggressive cancer subtypes.
AstraZeneca is conducting a Phase I clinical study titled A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886). The study aims to evaluate the safety and tolerability of AZD6244, an oral drug, in combination with standard chemotherapies for patients with advanced solid tumors. This research is significant as it seeks to establish the highest tolerated dose and understand the drug’s pharmacokinetics.
Study Overview: AstraZeneca, in collaboration with Acerta Pharma BV, is conducting a Phase 3 study titled A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma. The study aims to evaluate the efficacy of acalabrutinib combined with bendamustine and rituximab (BR) against a placebo plus BR in improving progression-free survival for patients with untreated mantle cell lymphoma.
The recent clinical study update from AstraZeneca and Bayer focuses on the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD5305 in combination with new hormonal agents for patients with metastatic prostate cancer. Officially titled ‘A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA),’ this study aims to explore innovative treatment options for a challenging condition.
AstraZeneca is conducting a real-world study titled ‘Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)’ in Germany. The study aims to evaluate the usage of dapagliflozin in patients with heart failure, focusing on treatment patterns, symptoms, and the impact on health-related quality of life and healthcare utilization.
AstraZeneca has recently completed a Phase 2a clinical study titled A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. The study aimed to assess the safety, tolerability, and pharmacokinetic profile of AZD2389, a drug intended to treat liver fibrosis and compensated cirrhosis, compared to a placebo.
AstraZeneca’s ongoing clinical study, titled A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer, aims to evaluate the effectiveness and safety of combining Durvalumab and Olaparib as a treatment for patients with advanced bladder cancer who cannot undergo platinum-based chemotherapy.
AstraZeneca is conducting a Phase I clinical study titled A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies. The study aims to evaluate the safety, tolerability, and pharmacokinetics of AZD6244, a drug intended for patients with advanced solid malignancies.
AstraZeneca’s latest clinical study, titled ‘Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania,’ aims to evaluate the real-world outcomes of acalabrutinib in Romanian patients with chronic lymphocytic leukemia (CLL). The study’s primary objective is to assess the time to treatment discontinuation, while secondary objectives include understanding the reasons for discontinuation, treatment effectiveness, and patient demographics.
AstraZeneca is conducting a Phase I clinical study titled ‘Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours.’ The study aims to evaluate the safety, tolerability, and pharmacokinetics of the combination of AZD1775, an oral drug, and MEDI4736, administered intravenously, in patients with refractory solid tumors.
AstraZeneca is conducting a clinical study titled ‘Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)’. The study aims to assess the efficacy and safety of combining capivasertib with CDK4/6 inhibitors and fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer. This research is significant as it explores new treatment combinations for a high-risk patient population.
AstraZeneca has initiated a Phase 2b study titled ‘APPRECIATE’ to evaluate the efficacy, safety, and tolerability of AZD2373 in participants with APOL1-Mediated Kidney Disease (AMKD). The study aims to demonstrate that AZD2373 can significantly reduce urinary albumin-to-creatinine ratio (UACR) compared to a placebo, offering a potential breakthrough for individuals with high-risk APOL1 genotypes.
AstraZeneca is conducting a Phase I/II study titled ‘ATHENA’ to evaluate the safety and efficacy of AZD5851, a CAR-T cell therapy, in adults with advanced or recurrent hepatocellular carcinoma (HCC) that expresses GPC3. This study is significant as it targets a specific protein, GPC3, which is prevalent in HCC, aiming to provide a new treatment avenue for patients who have not responded to previous therapies.
AstraZeneca has recently completed a Phase II clinical study titled A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation. The study aimed to evaluate the efficacy and safety of the drug Olaparib in patients with advanced cancers possessing BRCA1 or BRCA2 mutations, focusing on tumor response rates.
AstraZeneca’s latest clinical study, titled A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01), aims to evaluate the efficacy and safety of AZD0901. This study focuses on patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin18.2, a significant target in cancer treatment.
AstraZeneca, in collaboration with Parexel International, has completed a Phase I clinical study titled A Phase I, Randomised, Single-dose, Open-label, 3-period, 3-treatment, 3-way Crossover Study to Assess the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants. The study aimed to evaluate how food affects the pharmacokinetics of balcinrenone/dapagliflozin and the impact of a P-gp inhibitor on balcinrenone in healthy individuals.
AstraZeneca is currently conducting the iCaReMe Global Registry study, officially titled ‘Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases.’ The study aims to gather real-world data on patient characteristics, disease management, healthcare utilization, and outcomes for these conditions, highlighting its significance in improving patient care globally.
AstraZeneca is currently conducting a national multicenter non-interventional study titled ‘National Multicentre Non-interventional Study to Assess CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia.’ The study aims to evaluate the patterns and short-term outcomes of chemo-radiation therapy (CRT) in patients with unresectable non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in Russia, involving 2000 patients across 50 oncology centers.
AstraZeneca has launched a real-world study titled Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia. The study aims to evaluate the efficacy of Tezepelumab in treating severe asthma across different phenotypes in Russia, focusing on patient-reported outcomes.
AstraZeneca has launched the Chronic Kidney Disease Registry Platform Study, a multicenter, prospective, observational study aimed at establishing a comprehensive CKD registry in China. The study’s primary goal is to collect extensive data on the demographics, etiology, clinical characteristics, and treatment patterns of CKD patients, which will help identify gaps in current treatment guidelines and develop predictive models for disease progression and outcomes.
AstraZeneca is currently conducting a Phase III study titled ‘A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death.’ The study aims to assess the effectiveness of combining Baxdrostat with Dapagliflozin in reducing heart failure incidents and cardiovascular deaths among patients with type 2 diabetes and cardiovascular disease.
AstraZeneca has launched a Phase III clinical study titled ‘A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer’. The study aims to evaluate the efficacy and safety of the experimental drug Dato-DXd, with or without durvalumab, against standard chemotherapy options combined with pembrolizumab in treating patients with advanced triple-negative breast cancer.
AstraZeneca is conducting a Phase 3 study titled ‘A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus.’ The study aims to evaluate the efficacy and safety of subcutaneous anifrolumab in adults with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This research is significant as it targets improving treatment options for SLE, a challenging autoimmune disease.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase Ib study titled ‘DESTINY-Lung03’ to evaluate the safety and tolerability of Trastuzumab Deruxtecan (T-DXd) combined with immunotherapy agents, with or without chemotherapy, in patients with advanced or metastatic HER2+ non-squamous non-small cell lung cancer (NSCLC). This study aims to identify effective first-line treatment options for this patient group.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase II clinical study titled ‘DESTINY PanTumor03.’ The study aims to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) as a monotherapy or in combination with other anti-cancer agents for treating patients with selected HER2-expressing tumors. This research is significant as it targets locally advanced, unresectable, or metastatic tumors that are not eligible for curative therapy.
AstraZeneca’s recent clinical study update focuses on a Phase II trial titled A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene. The study aims to evaluate the safety and efficacy of AZD9291 in treating advanced non-small cell lung cancer (NSCLC) in patients whose disease has progressed despite prior treatments.
AstraZeneca is conducting a study titled ‘Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH).’ The study aims to evaluate the real-world effectiveness of Ravulizumab, a drug used in routine clinical practice for treating PNH, by collecting data on patient characteristics and clinical outcomes.
AstraZeneca is conducting a study titled A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared With BDA Delivered by MDI HFA in Participants With Asthma. The study aims to evaluate the pharmacodynamic equivalence of the approved asthma therapy BDA when delivered with a new propellant, HFO, compared to the currently approved HFA propellant in patients with asthma. This research is significant as it could lead to improved asthma treatments with potentially lower environmental impact.
AstraZeneca is conducting a study titled ‘UmbREALung – A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance.’ The study aims to observe the real-world application of AstraZeneca-developed drugs in treating NSCLC across different stages, providing valuable insights into their effectiveness and safety.
AstraZeneca is currently conducting a clinical study titled ‘A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies.’ The study aims to assess the safety and efficacy of AZD0486, both as a standalone treatment and in combination with other anticancer agents, for patients with mature B-cell hematologic malignancies. This study is significant as it explores potential new treatments for challenging cancer types.
AstraZeneca has launched a significant clinical study titled ‘Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD).’ The study aims to observe and analyze the rate of chronic kidney disease (CKD) diagnosis in patients with arterial hypertension in Kazakhstan. This research is crucial in understanding the prevalence and progression of CKD in this demographic, potentially guiding future treatment strategies.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase III clinical trial to evaluate the safety and efficacy of AZD9291 compared to standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. The study targets patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for EGFR mutations. This trial is significant as it aims to improve first-line treatment options for this patient group.
AstraZeneca is conducting a Phase III clinical study titled ‘A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure.’ The study aims to evaluate the effectiveness and safety of combining baxdrostat with dapagliflozin in treating CKD in patients with high blood pressure.
AstraZeneca has initiated a Phase 3 clinical trial titled ‘Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS).’ The study aims to assess the safety, tolerability, and pharmacokinetics of benralizumab in children with rare eosinophilic diseases, marking a significant step in pediatric treatment options for these conditions.
AstraZeneca is conducting a prospective non-interventional study titled Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing. The study aims to gather real-world data on the treatment of advanced high-grade epithelial ovarian cancer in Germany, focusing on the effects of first-line Poly ADP ribose polymerase inhibitor (PARPi) maintenance treatment.
AstraZeneca is conducting a Phase I study titled ‘A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234.’ The study aims to evaluate the pharmacokinetics, safety, and tolerability of AZD6234 in patients with varying degrees of renal impairment compared to healthy controls. This research is significant as it could inform dosing guidelines for patients with renal issues.
AstraZeneca is conducting a Phase 1b/2 clinical study titled ‘A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety, tolerability, and efficacy of GC012F (AZD0120) in treating relapsed/refractory multiple myeloma, a significant area of unmet medical need.
AstraZeneca is conducting a significant Phase 2b clinical study titled A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele. The study aims to assess the efficacy, safety, and tolerability of the drug AZD2693 in adult participants with NASH and fibrosis who carry the PNPLA3 148M risk allele, a genetic variant associated with liver disease.
AstraZeneca is conducting a Phase III study titled ‘ZENITH High Proteinuria’ to evaluate the efficacy, safety, and tolerability of a combination treatment of Zibotentan and Dapagliflozin compared to Dapagliflozin alone in patients with chronic kidney disease (CKD) and high proteinuria. This study aims to provide insights into more effective treatments for CKD, a condition with significant health implications.
AstraZeneca is conducting a Phase III clinical study titled A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES). The study aims to assess the efficacy and safety of benralizumab in treating patients with HES, a rare and potentially life-threatening condition characterized by high levels of eosinophils.
AstraZeneca is currently conducting a study titled ‘Anifrolumab Real-world Treatment Outcomes in Polish Patients With Systemic Lupus Erythematosus (SLE).’ This multicenter, non-interventional study aims to gather data on the characteristics and clinical outcomes of patients with SLE treated with anifrolumab in routine clinical practice in Poland. The study’s significance lies in its potential to provide real-world evidence of anifrolumab’s effectiveness and safety, which could inform future treatment strategies for SLE.
AstraZeneca, in collaboration with Ionis Pharmaceuticals, is conducting a Phase 3 study titled ‘CARDIO-TTRansform’ to evaluate the efficacy and safety of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). The study aims to assess how well eplontersen, administered via subcutaneous injections, performs compared to a placebo in improving patient outcomes while receiving standard care.
The EXCEED study, officially titled ‘A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs,’ aims to assess the risk of pancreatic cancer in type 2 diabetes patients starting exenatide versus other glucose-lowering drugs. This study is significant as it evaluates potential long-term safety concerns associated with exenatide, a commonly used diabetes medication.
AstraZeneca is currently recruiting participants for a Phase III clinical study titled A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis). The study aims to evaluate the efficacy and safety of anifrolumab, a subcutaneous injection, in treating moderate to severe idiopathic inflammatory myopathies, specifically polymyositis and dermatomyositis, alongside standard care.
AstraZeneca has recently completed a clinical study titled ‘Hyperkalemia Registry An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart Failure.’ The study aimed to evaluate the long-term management of hyperkalemia, focusing on treatment adherence and health-related quality of life in patients with chronic kidney disease or heart failure.
Study Overview: The ARTEMIDE-Lung03 study, officially titled ‘A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1,’ aims to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with chemotherapy, for treating metastatic non-squamous NSCLC expressing PD-L1.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 2 clinical study titled ‘TROPION-Lung05’ to evaluate the efficacy, pharmacokinetics, and safety of DS-1062a in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with actionable genomic alterations. This study is significant as it targets patients who have already undergone platinum-based chemotherapy and targeted therapy, aiming to provide new treatment options.
AstraZeneca is currently conducting a study titled ‘PANGEIA-2: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.’ This observational study aims to assess the prevalence of emerging ESR1 mutations in patients with breast cancer, comparing those with and without prior therapies in a metastatic setting. The study’s significance lies in its potential to enhance understanding of mutation prevalence and inform future therapeutic strategies.
AstraZeneca has announced a new clinical study titled ‘Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer (STAR-BREAST).’ The study aims to evaluate an AI-based tool designed to predict genetic risk for breast cancer, focusing on women identified as high-risk by specialists. This tool, developed by WeConecta, will gather data via WhatsApp to assess family cancer history, offering significant potential in early detection and personalized treatment strategies.
AstraZeneca is conducting a clinical study titled A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors. The study aims to assess the safety and tolerability of AZD8421, both as a standalone treatment and in combination with other targeted anti-cancer drugs, in patients with advanced breast and ovarian cancers. This research is significant as it explores new treatment avenues for these challenging cancer types.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase II study titled ‘NeoCOAST-2’ to evaluate the safety and efficacy of various drug combinations in treating resectable, early-stage non-small cell lung cancer (NSCLC). The study aims to explore the potential of neoadjuvant and adjuvant treatments in improving patient outcomes.
AstraZeneca is conducting a Phase III clinical study titled ‘Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen.’ The study aims to assess the effectiveness of tozorakimab, an investigational drug, in preventing death or the need for invasive mechanical ventilation or extracorporeal membrane oxygenation in hospitalized patients with viral lung infections.
AstraZeneca is conducting a Phase I clinical study titled A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD8965 Following Single and Multiple Ascending Dose Administration to Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants. The study aims to evaluate the safety, tolerability, and pharmacokinetics of AZD8965, a new drug, in healthy individuals, including Japanese and Chinese participants, and to understand how food affects its pharmacokinetics.
AstraZeneca is conducting a study titled ‘A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 (CAMPOLINA).’ The study aims to evaluate the safety and tolerability of AZD2389 in individuals with varying degrees of liver impairment compared to those with normal liver function.
Study Overview: AstraZeneca is conducting a prospective non-interventional study titled ‘Prospective Non-interventional Study (NIS) to Examine the Effectiveness of Tremelimumab + Durvalumab + Platinum Chemotherapy (TDC) in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations.’ The study aims to gather real-world data on the effectiveness of TDC treatment in patients with metastatic non-squamous non-small cell lung cancer (mNSCLC) with specific genetic alterations, enhancing biomarker-guided treatment strategies.
AstraZeneca recently completed a Phase 1 clinical study titled ‘A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Japanese Subjects With Advanced Solid Tumors.’ The study aimed to assess the safety and tolerability of MEDI5752, a biological treatment, in Japanese patients with advanced solid tumors. The significance of this study lies in its potential to offer a new therapeutic option for this patient group.
AstraZeneca, in collaboration with Merck Sharp & Dohme LLC, is conducting a study titled ‘A Prospective Observational Study to Evaluate Real-world Clinical Outcomes and Characteristics of Patients With mCRPC Treated With Olaparib + Abiraterone.’ The study aims to assess the real-world clinical outcomes and characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the combination of olaparib and abiraterone. This research is significant as it provides insights into the effectiveness of this treatment in a real-world setting, potentially influencing future therapeutic strategies.
AstraZeneca is conducting a Phase II clinical study titled ‘A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA).’ The study aims to evaluate the efficacy and safety of osimertinib as an induction therapy before curative intent chemoradiotherapy (CRT) and as a maintenance therapy in adult patients with Stage III, unresectable non-small cell lung cancer (NSCLC) with common EGFR mutations. The significance of this study lies in its potential to improve treatment outcomes for this specific patient group.
AstraZeneca’s latest clinical study, titled ‘An Open-label, Fixed-sequence, Three-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and to Assess the Effect of Erythromycin on AZD5004 in Healthy Participants,’ aims to evaluate the interactions of AZD5004 with several commonly used drugs. The study’s primary objective is to understand how AZD5004 affects the pharmacokinetics of these drugs in healthy individuals, which is crucial for determining safe and effective dosage regimens.
AstraZeneca is currently conducting a Phase III study titled ‘A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma.’ The study aims to evaluate the efficacy and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, in patients with advanced hepatocellular carcinoma (HCC) who are not eligible for curative or locoregional therapy.
Study Overview: AstraZeneca is conducting a real-world treatment study titled ‘Real-World Treatment Study of Koselugo (Selumetinib)’ to evaluate the safety and effectiveness of Koselugo in routine clinical practice settings in Korea. This study aims to provide insights into the safety profile and effectiveness of the drug, particularly focusing on the Korean patient population.
AstraZeneca is currently conducting a study titled ‘A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)’. The study aims to assess the safety, tolerability, and efficacy of AZD5492, a novel T cell-engaging antibody, in treating relapsed or refractory B-cell malignancies.
AstraZeneca’s latest clinical study, officially titled A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso), aims to evaluate the efficacy and safety of Volrustomig (MEDI5752) combined with Carboplatin and Pemetrexed. This study is significant as it targets unresectable pleural mesothelioma, a challenging cancer type, potentially offering new treatment avenues.
AstraZeneca is conducting a Phase II study titled ‘A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer.’ The study aims to evaluate the efficacy and safety of adding olaparib to a standard chemotherapy regimen in patients with advanced ovarian cancer, potentially offering a new treatment avenue for this challenging condition.
AstraZeneca is conducting a retrospective study titled ‘Retrospective Real World Evidence Study to Describe Characteristics and Outcomes in Dutch Patients Admitted to the Hospital With a Factor Xa Inhibitor-associated Bleeding Treated With Andexanet Alfa.’ The study aims to gather real-world data on patient characteristics and outcomes for those treated with andexanet alfa in Dutch hospitals, addressing the need for a clearer patient profile due to its comparable status with PCC in national guidelines.
AstraZeneca, in collaboration with Parexel International, is set to commence a clinical study titled A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation. The study aims to evaluate the effects of the BGF MDI compared to a placebo on heart and lung function in COPD patients, highlighting its potential significance in improving treatment outcomes for this condition.
Study Overview: AstraZeneca is conducting a Phase II study titled Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist. The study aims to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes, who are already on stable GLP-1 RA therapy. This research is significant as it could provide a new treatment option for managing type 2 diabetes in this population.
AstraZeneca has launched a global Phase III study titled ‘A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of volrustomig combined with chemotherapy compared to pembrolizumab with chemotherapy for first-line treatment in patients with metastatic non-small cell lung cancer (mNSCLC) with PD-L1 < 50%.
AstraZeneca has recently completed a Phase 1 clinical study titled ‘A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer.’ The study aimed to evaluate the safety and tolerability of AZD9833, a promising treatment for endocrine-resistant ER+ HER2- breast cancer, which is not suitable for curative treatment. This study is significant as it explores new therapeutic options for a challenging cancer type.
Amgen Inc and AstraZeneca have announced a new clinical study titled A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON). This study aims to evaluate the efficacy and safety of tezepelumab, a potential treatment for pediatric patients with severe uncontrolled asthma, highlighting its significance in addressing unmet medical needs in this demographic.
AstraZeneca’s latest clinical study, officially titled ‘A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE),’ aims to evaluate the safety and efficacy of durvalumab combined with gemcitabine-based chemotherapy in patients with advanced biliary tract cancers (aBTCs). This study is significant as it explores potential first-line treatment options for this challenging condition.
AstraZeneca has launched the Hyperkalemia Quality Improvement Program (HK-QIP) Study, officially titled ‘A Prospective, Multicenter, Single Arm Study to Evaluate the Impact on the Implementation of Standardized Hyperkalemia Management in Chronic Kidney Disease Patients.’ This study aims to assess the effectiveness of standardized hyperkalemia management in non-dialysis chronic kidney disease (CKD-ND) patients, particularly in China. The significance lies in improving medical care processes and clinical outcomes for these patients.
AstraZeneca is currently conducting a Phase I study titled ‘A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels.’ The study aims to evaluate the safety and effectiveness of AZD4954 in healthy adults, focusing on those with varying levels of Lipoprotein(a), a known cardiovascular risk factor.
AstraZeneca’s recent study, titled ‘EXACERBATIONS AND REAL-WORLD OUTCOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study),’ aims to assess the timing of Budesonide/Glycopyrronium/Formoterol (BGF) initiation after an exacerbation and its impact on subsequent exacerbations and cardiopulmonary events in COPD patients.
AstraZeneca has launched a new clinical study titled ‘A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician’s Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)’. The study aims to demonstrate the superiority of Saruparib combined with new hormonal agents over a placebo in improving radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer.
AstraZeneca, in collaboration with Daiichi Sankyo and Merck Sharp & Dohme LLC, is conducting a Phase 3 clinical study titled ‘TROPION-Lung08.’ The study aims to evaluate the efficacy and safety of combining datopotamab deruxtecan (Dato-DXd) with pembrolizumab versus pembrolizumab alone in treating advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations.
AstraZeneca, in collaboration with Parexel, is conducting a Phase I study titled ‘A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies.’ The study aims to evaluate the safety and pharmacokinetics of saruparib, a drug designed to treat advanced solid tumors, and its interaction with other medications.
AstraZeneca is spearheading a new observational study titled ‘DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns.’ The study aims to evaluate treatment patterns in patients with advanced non-small cell lung carcinoma (NSCLC) to ensure alignment with clinical guidelines. This research is significant as it seeks to enhance understanding of treatment choices in real-world settings, potentially influencing future clinical practices.
The recent clinical study update from AstraZeneca focuses on the prevalence and clinical characteristics of Hereditary Transthyretin Amyloidosis Polyneuropathy (ATTR PN) in Russian patients with Carpal Tunnel Syndrome (CTS). Officially titled ‘A Multicenter Observational Retrospective-prospective Study of Prevalence, Clinical Characteristics of Hereditary Transthyretin Amyloidosis Polyneuropathy in Russian Patients Undergoing Surgery for CTS in Real Clinical Practice,’ the study aims to gather crucial epidemiological data and improve patient outcomes by identifying early-stage ATTR PN, which is often misdiagnosed.
The MaesTTRo study, officially titled ‘A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis,’ aims to collect comprehensive data on patients with ATTR amyloidosis. This study seeks to understand the natural progression of the disease and evaluate treatment patterns and outcomes, particularly focusing on the effectiveness of treatments like eplontersen.
AstraZeneca is currently recruiting for a clinical study titled ‘Boosting Regional Integration for COPD Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle.’ The study aims to enhance COPD care by implementing a transition bundle at the hospital level, focusing on education, standardized practices, and clinical audits. This initiative is significant as it seeks to improve post-exacerbation care in COPD patients, potentially setting a new standard for treatment.
Study Overview: AstraZeneca is conducting a Phase 1 clinical study titled Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors. The study aims to assess the safety and initial anti-tumor effects of TCR-engineered T cells targeting KRAS mutations, a significant advancement for patients with advanced solid tumors.
Study Overview: AstraZeneca is conducting a multicenter, prospective cohort study titled A Study in Patients With Myasthenia Gravis in China. The study aims to characterize clinical practices, outcomes, disease prognosis, and treatment patterns for patients with myasthenia gravis (MG) in China. Approximately 1,200 patients will be recruited from around 40 sites, providing significant insights into MG management in the region.
AstraZeneca’s latest clinical study, titled the ‘Non-alcoholic Steatohepatitis Registry Platform Study,’ aims to explore the clinical characteristics and treatment patterns of Chinese patients with non-alcoholic steatohepatitis (NASH) with fibrosis. This multi-center, prospective, observational study seeks to gather real-world data to enhance clinical practice and guide the development of NASH drugs in China.
AstraZeneca has initiated a Phase I clinical study titled ‘A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors.’ This study aims to evaluate the safety, tolerability, and preliminary efficacy of AZD9592, both as a standalone treatment and in combination with other anti-cancer agents, in patients with advanced solid tumors.
AstraZeneca, in collaboration with Foundation Medicine and other industry partners, is conducting a clinical study titled ‘A Randomized, Open-label Study to Assess the Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Chinese Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (PROfound-CN)’. The study aims to evaluate the effectiveness and safety of Olaparib, a targeted cancer therapy, compared to standard treatments in a specific patient group.